BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 6057803)

  • 1. Cryptococcus neoformans. I. Nonencapsulated mutants.
    Bulmer GS; Sans MD; Gunn CM
    J Bacteriol; 1967 Nov; 94(5):1475-9. PubMed ID: 6057803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gas-chromatographic study of the carbohydrates in Cryptococcus neoformans, in relation to the antigenic characteristics and virulence of the strains].
    Gargani G; Grasso C
    Boll Soc Ital Biol Sper; 1968 Dec; 44(23):2026-8. PubMed ID: 5735776
    [No Abstract]   [Full Text] [Related]  

  • 3. Cryptococcus neoformans. II. Phagocytosis by human leukocytes.
    Bulmer GS; Sans MD
    J Bacteriol; 1967 Nov; 94(5):1480-3. PubMed ID: 4862192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased virulence in stable, acapsular mutants of cryptococcus neoformans.
    Fromtling RA; Shadomy HJ; Jacobson ES
    Mycopathologia; 1982 Jul; 79(1):23-9. PubMed ID: 6750405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations on the structure of the capsular polysaccharide from Cryptococcus neoformans type B.
    Blandamer A; Danishefsky I
    Biochim Biophys Acta; 1966 Apr; 117(2):305-13. PubMed ID: 5961297
    [No Abstract]   [Full Text] [Related]  

  • 6. Susceptibility of congenitally immunodeficient mice to a nonencapsulated strain of Cryptococcus neoformans.
    Salkowski CA; Balish E
    Can J Microbiol; 1991 Nov; 37(11):834-9. PubMed ID: 1777860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.
    Cherniak R; Reiss E; Slodki ME; Plattner RD; Blumer SO
    Mol Immunol; 1980 Aug; 17(8):1025-32. PubMed ID: 6777664
    [No Abstract]   [Full Text] [Related]  

  • 8. Mannosyl transfer in Cryptococcus laurentii.
    Garancis JC; Ankel H; Ankel E; Schutzbach JS
    J Biol Chem; 1970 Aug; 245(15):3945-55. PubMed ID: 5492958
    [No Abstract]   [Full Text] [Related]  

  • 9. On the structure of the capsular polysaccharide from Cryptococcus neoformans serotype C--II.
    Bhattacharjee AK; Kwon-Chung KJ; Glaudemans CP
    Mol Immunol; 1979 Jul; 16(7):531-2. PubMed ID: 387576
    [No Abstract]   [Full Text] [Related]  

  • 10. Structure of the O-deacetylated glucuronoxylomannan from Cryptococcus neoformans Cap70 as determined by 2D NMR spectroscopy.
    Bacon BE; Cherniak R; Kwon-Chung KJ; Jacobson ES
    Carbohydr Res; 1996 Mar; 283():95-110. PubMed ID: 8901265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptococcus neoformans. 3. Inhibition of phagocytosis.
    Bulmer GS; Sans MD
    J Bacteriol; 1968 Jan; 95(1):5-8. PubMed ID: 4866104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urease activity in Cryptococcus neoformans and Cryptococcus gattii].
    Torres-Rodríguez JM; Alvarado-Ramírez E; Gutiérrez-Gallego R
    Rev Iberoam Micol; 2008 Mar; 25(1):27-31. PubMed ID: 18338924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encapsulation and melanin formation as indicators of virulence in Cryptococcus neoformans.
    Kwon-Chung KJ; Rhodes JC
    Infect Immun; 1986 Jan; 51(1):218-23. PubMed ID: 3079732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of pathogenic constituents of Cryptococcus neoformans strains.
    Kagaya K; Yamada T; Miyakawa Y; Fukazawa Y; Saito S
    Microbiol Immunol; 1985; 29(6):517-32. PubMed ID: 3900645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strain variation in composition and molecular size of the capsular polysaccharide of Cryptococcus neoformans serotype A.
    Small JM; Mitchell TG; Wheat RW
    Infect Immun; 1986 Dec; 54(3):735-41. PubMed ID: 3536746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide.
    Granger DL; Perfect JR; Durack DT
    J Clin Invest; 1985 Aug; 76(2):508-16. PubMed ID: 3928681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptococcus neoformans: size range of infectious particles from aerosolized soil.
    Neilson JB; Fromtling RA; Bulmer GS
    Infect Immun; 1977 Sep; 17(3):634-8. PubMed ID: 332630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic capsule gene disruption reveals the central role of galactose metabolism on Cryptococcus neoformans virulence.
    Moyrand F; Fontaine T; Janbon G
    Mol Microbiol; 2007 May; 64(3):771-81. PubMed ID: 17462022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and electron microscopic changes in gamma radiated Cryptococcus neoformans.
    Dembitzer HM; Buza I; Reiss F
    Mycopathol Mycol Appl; 1972 Aug; 47(3):307-15. PubMed ID: 4116042
    [No Abstract]   [Full Text] [Related]  

  • 20. Capsular polysaccharides of Cryptococcus neoformans.
    Bhattacharjee AK; Bennett JE; Glaudemans CP
    Rev Infect Dis; 1984; 6(5):619-24. PubMed ID: 6209768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.